1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level

doi:10.1016/S0006-8993(96)00917-1

Brain Research

Volume 741, Issues 1–2, 25 November 1996, Pages 185-196

https://doi.org/10.1016/S0006-8993(96)00917-1 Get rights and content

Abstract

The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been shown to induce parkinsonism in man and non-human primates. Hypotheses concerning the mechanism of action of MPTP have been related to the pathogenesis of nigral cell death in Parkinson's disease. For instance, alterations of calcium influxes have been reported to be implicated in both MPTP-induced parkinsonism and Parkinson's disease. Recently, we reported that nimodipine, a blocker of L-type calcium channels, prevents dopaminergic MPTP-induced neurotoxicity in C57B1/6 black mice. The present study extended these rodent findings to the non-human primate model of Parkinson's disease and assessed the effects of nimodipine, continuously applied by pellet for 18 days, on behavioural, biochemical and histological parameters, following systemic application of MPTP in common marmosets (Callithrix jacchus). The experimental design involved five groups of common marmosets and a total of 24 animals. Monkeys assigned to group I (n = 4) received subcutaneously implanted vehicle pellets 7 days prior to subcutaneous saline injections (control). Monkeys of group II (n = 4) were treated with nimodipine pellets (80 mg) and saline injections. Marmosets in group III (n = 8) were treated with vehicle pellets and received 4 times MPTP (MPTP-HCI, 2 mg/kg body weight subcutaneously, separated by an interval of 24 h for a total of 4 days). Monkeys in group IV (n = 4) and V (n = 4) were treated as group-III animals except for the implantation of nimodipine pellets (80 mg and 120 mg, respectively) 7 days prior to toxin exposure. In common marmosets MPTP induced severe parkinsonian symptoms, a pronounced dopamine depletion in the caudate-putamen (more than 99% of control) and a loss of tyrosine hydroxylase immunoreactive cells in the substantia nigra (50% percent of control) 7 days after MPTP-administration. Pretreatment with nimodipine (120 mg pellets) did neither attenuate the behavioural impairments in MPTP-treated animals nor antagonize the striatal neurotoxin-induced dopamine depletion, but almost completely prevented (in a dose-dependent manner) the MPTP-induced decrease of nigral tyrosine hydroxylase immunoreactive cells. These data suggest that application of nimodipine, during the observation period of 7 days, protects against MPTP-induced neurotoxicity in common marmosets at the cellular nigral level, but not at the synaptic striatal level, implicating differential mechanisms of actions of MPTP-induced neurotoxicity at the nigral versus the striatal level.

References (59)

AlbaneseA. et al.
Chronic administration of l-methyl-4-phenyl1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates
Neuroscience
(1993)
BenazzouzA. et al.
Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study
Eur. J. Pharmacol.
(1995)
CampbellK.T. et al.
Evidence for retrograde axonal transport of MPP⁺ in the rat
Neurosci. Lett.
(1990)
ChiuehC.C. et al.
Role of extracellular calcium ion on 1-methyl-4-phenylpyridine induced sustained exocytosis of endogenous striatal dopamine in vivo
Eur. J. Pharmacol.
(1990)
DavisG.C. et al.
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Psychiatry Res.
(1979)
DeckertJ. et al.
Nimodipine inhibits (³H)nitroben-zylthioinosine binding to the adenosine transporter in human brain
Eur. J. Pharmacol.
(1993)
FingerS. et al.
Nimodipine enhances growth and vascularization of neural grafts
Exp. Neurol.
(1989)
FreiB. et al.
N-Methyl-4-phenylpyridine (MPP⁺) together with 6-hydroxydopamine or dopamine stimulates Ca-release from mitochondria
FEBS Lett.
(1986)
GerlachM. et al.
Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin
Neurochem. Int.
(1996)
GerlachM. et al.
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
Eur. J. Pharmacol. Mol. Pharmacol. Sect.
(1991)

HantrayeP. et al.

Stable Parkinsonian syndrome and uneven loss of dopamine fibres following chronic MPTP administration in baboons

Neuroscience

(1993)

HerkenhamM. et al.

Selective retention of MPP⁺ within the monaminergic system of the primate brain following MPTP administration: an in vivo autoradiographic study

Neuroscience

(1991)

Jackson-LewisV. et al.

Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Neurodegeneration

(1995)

JennerP. et al.

1-Methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-induced parkinsonism in the common marmoset

Neurosci. Lett.

(1984)

JohannessenJ.N. et al.

Differences in metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects

Life Sci.

(1985)

KassG.E.N. et al.

The mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity, role of intracellular calcium

Arch. Biochem. Biophys.

(1988)

KittC.A. et al.

Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey

Neuroscience

(1986)

KupschA. et al.

Do NMDA receptor antagonists protect against MPTP toxicity? Biochemical and immunocytochemical analyses in a mouse model of Parkinson's disease

Brain Res.

(1992)

NishinoN.N. et al.

[³H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease

Brain Res.

(1986)

Pérez-Otan˜oI. et al.

Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in common marmosets

Brain Res.

(1991)

ReinhardJ.F. et al.

Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse; evidence for subcellular sequestration as basis for cellular resistance to the toxicant

Neurosci. Lett.

(1988)

SchneiderJ.S. et al.

Chronic exposure to low doses of MPTP: 1. Cognitive deficits motor asymptomatic monkeys

Brain Res.

(1990)

SeniukN.A. et al.

Dose-dependent destruction of the coeruleus-cortical and the nigrostriatal projections by MPTP

Brain Res.

(1990)

SirinathsinghjiD.J.S. et al.

Dopamine-releasing action of 1-methyl-4-phenylpyridinium (MPP⁺) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique, dependence on sodium but not calcium

Brain Res.

(1988)

TakadaM. et al.

Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons

Brain Res.

(1992)

TattonW.G. et al.

MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells

Brain Res.

(1990)

YamadaT. et al.

Relative sparing in Parkinson's disease of substantia nigra neurons containing calbindin-D28K

Brain Res.

(1990)

AzmitiaE.C.

Nimodipine attenuates NMDA- and MDMA-induced toxicity of cultured fetal serotonergic neurons: evidence for a generic model of calcium toxicity

BurnsR.S. et al.

A primate model of parkinsonism: selective destruction of dopaminergic neuons in the pars compacta of the substantia nigra byN-methyl-4-phenyl-1,2,3,6-tetryhydropyridine

Cited by (90)

Molecular mechanism of cognitive impairment associated with Parkinson's disease: A stroke perspective
2024, Life Sciences
Parkinson's disease (PD) is a common neurological illness that causes several motor and non-motor symptoms, most characteristically limb tremors and bradykinesia. PD is a slowly worsening disease that arises due to progressive neurodegeneration of specific areas of the brain, especially the substantia nigra of the midbrain. Even though PD has continuously been linked to a higher mortality risk in numerous epidemiologic studies, there have been significant discoveries regarding the connection between PD and stroke. The incidence of strokes such as cerebral infarction and hemorrhage is substantially associated with the development of PD. Moreover, cognitive impairments, primarily dementia, have been associated with stroke and PD. However, the underlying molecular mechanism of this phenomenon is still obscure. This concise review focuses on the relationship between stroke and PD, emphasizing the molecular mechanism of cognition deficit and memory loss evident in PD and stroke. Furthermore, we are also highlighting some potential drug molecules that can target both PD and stroke.
Nimodipine attenuates the parkinsonian neurotoxin, MPTP-induced changes in the calcium binding proteins, calpain and calbindin
2019, Journal of Chemical Neuroanatomy
We have recently demonstrated neuroprotective abilities of nimodipine, an L-type voltage dependent calcium channel (VDCC) blocker in cellular and animal models of Parkinson's disease (PD). To understand the calcium regulatory mechanisms in the disease pathogenesis, the present study examined calcium regulatory proteins calbindin and calpain mRNA and protein levels employing quantitative PCR and western blot in 1-methyl-4-phenyl pyridinium ion (MPP⁺)-treated SH-SY5Y cell lines and in the striatum of mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). mRNA and protein levels of calbindin were lower, while that of calpain were higher in MPP⁺-treated SH-SY5Y cells and MPTP-treated mouse striatum as compared to their respective controls. Nimodipine pretreatment significantly attenuated these effects in the parkinsonian neurotoxin-treated SH-SY5Y cell line and in the mouse striatum. The activities of the apoptotic mediator, caspase-3 and calpain were increased in the neurotoxin-treated groups as compared to their respective controls, which was ameliorated by nimodipine pretreatment. These results suggest that parkinsonian neurotoxin-mediated dopaminergic neuronal death might involve defects in calcium regulatory proteins that control intracellular calcium homeostasis, and these could be corrected by inhibiting L-type VDCC activity. These findings support the notion that hypertensive patients who are on long-term intake of dihydropyridine have reduced risk for PD.
Altered function of neuronal L-type calcium channels in ageing and neuroinflammation: Implications in age-related synaptic dysfunction and cognitive decline
2018, Ageing Research Reviews
The rapid developments in science have led to an increase in human life expectancy and thus, ageing and age-related disorders/diseases have become one of the greatest concerns in the 21st century. Cognitive abilities tend to decline as we get older. This age-related cognitive decline is mainly attributed to aberrant changes in synaptic plasticity and neuronal connections. Recent studies show that alterations in Ca²⁺ homeostasis underlie the increased vulnerability of neurons to age-related processes like cognitive decline and synaptic dysfunctions. Dysregulation of Ca²⁺ can lead to dramatic changes in neuronal functions. We discuss in this review, the recent advances on the potential role of dysregulated Ca²⁺ homeostasis through altered function of L-type voltage gated Ca²⁺ channels (LTCC) in ageing, with an emphasis on cognitive decline. This review therefore focuses on age-related changes mainly in the hippocampus, and with mention of other brain areas, that are important for learning and memory. This review also highlights age-related memory deficits via synaptic alterations and neuroinflammation. An understanding of these mechanisms will help us formulate strategies to reverse or ameliorate age-related disorders like cognitive decline.
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease
2017, Neuroscience
Parkinson’s disease is a common, debilitating, neurodegenerative disorder for which the current gold standard treatment, levodopa (L-DOPA) is symptomatic. There is an urgent, unmet need for neuroprotective or, ideally, neuro-restorative drugs. We describe a 6-hydroxydopamine (6-OHDA) zebrafish model to screen drugs for neuroprotective and neuro-restorative capacity. Zebrafish larvae at two days post fertilization were exposed to 6-OHDA for three days, with co-administration of test drugs for neuroprotection experiments, or for 32 h, with subsequent treatment with test drugs for neuro-restoration experiments. Locomotor activity was assessed by automated tracking and dopaminergic neurons were visualized by tyrosine hydroxylase immuno-histochemistry. Exposure to 6-OHDA for either 32 h or 3 days induced similar, significant locomotor deficits and neuronal loss in 5-day-old larvae. L-DOPA (1 mM) partially restored locomotor activity, but was neither neuroprotective nor neuro-restorative, mirroring the clinical situation. The calcium channel blocker, isradipine (1 µM) did not prevent or reverse 6-OHDA-induced locomotor deficit or neuronal loss. However, both the tetracycline analog, minocycline (10 µM), and the monoamine oxidase B inhibitor, rasagiline (1 µM), prevented the locomotor deficits and neuronal loss due to three-day 6-OHDA exposure. Importantly, they also reversed the locomotor deficit caused by prior exposure to 6-OHDA; rasagiline also reversed neuronal loss and minocycline partially restored neuronal loss due to prior 6-OHDA, making them candidates for investigation as neuro-restorative treatments for Parkinson’s disease. Our findings in zebrafish reflect preliminary clinical findings for rasagiline and minocycline. Thus, we have developed a zebrafish model suitable for high-throughput screening of putative neuroprotective and neuro-restorative therapies for the treatment of Parkinson’s disease.
Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease
2017, Experimental Neurology
Parkinson's disease is characterized by progressively distributed Lewy pathology and neurodegeneration. The motor symptoms of clinical Parkinson's disease (cPD) are unequivocally linked to the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc). Several features of these neurons appear to make them selectively vulnerable to factors thought to cause cPD, like aging, genetic mutations and environmental toxins. Among these features, Ca^2 + entry through Cav1 channels is particularly amenable to pharmacotherapy in early stage cPD patients. This review outlines the linkage between these channels, mitochondrial oxidant stress and cPD pathogenesis. It also summarizes considerations that went into the design and execution of the ongoing Phase 3 clinical trial with an inhibitor of these channels – isradipine.
Calcium and Parkinson's disease
2017, Biochemical and Biophysical Research Communications
Citation Excerpt :
Unfortunately, there are no genetic animal models of PD with predictive validity. That said, inhibiting Cav1 channels diminishes the damage induced by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) when given at doses that produce partial loss of SNc DA neurons [38,108–110]. Inhibiting Cav1 channels also protects SNc DA neurons from low doses of the environmental toxin rotenone [38].
Parkinson's disease (PD) is the second most common neurodegenerative disease in the world. Its causes are poorly understood and there is no proven therapeutic strategy for slowing disease progression. The core motor symptoms of PD are caused by the death of dopaminergic neurons in the substantia nigra pars compacta (SNc). In these neurons, Ca²⁺entry through plasma membrane Cav1 channels drives a sustained feed-forward stimulation of mitochondrial oxidative phosphorylation. Although this design helps prevent bioenergetic failure when activity needs to be sustained, it leads to basal mitochondrial oxidant stress. Over decades, this basal oxidant stress could compromise mitochondrial function and increase mitophagy, resulting in increased vulnerability to other proteostatic stressors, like elevated alpha synuclein expression. Because this feedforward mechanism is no longer demanded by our lifestyle, it could be dispensed with. Indeed, use of dihydropyridines – negative allosteric modulators of Cav1 Ca²⁺ channels – comes with little or no effect on brain function but is associated with decreased risk and progression of PD. An ongoing, NIH sponsored, Phase 3 clinical trial in North America is testing the ability of one member of the dihydropyridine class (isradipine) to slow PD progression in early stage patients. The review summarizes the rationale for the trial and outlines some unanswered questions.

View all citing articles on Scopus

View full text

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level

Abstract

Neuroscience

Eur. J. Pharmacol.

Neurosci. Lett.

Eur. J. Pharmacol.

Psychiatry Res.

Eur. J. Pharmacol.

Exp. Neurol.

FEBS Lett.

Neurochem. Int.

Eur. J. Pharmacol. Mol. Pharmacol. Sect.

Neuroscience

Neuroscience

Neurodegeneration

Neurosci. Lett.

Life Sci.

Arch. Biochem. Biophys.

Neuroscience

Brain Res.

Brain Res.

Brain Res.

Neurosci. Lett.

Brain Res.

Brain Res.

Brain Res.

Brain Res.

Brain Res.

Brain Res.

Nimodipine attenuates NMDA- and MDMA-induced toxicity of cultured fetal serotonergic neurons: evidence for a generic model of calcium toxicity

A primate model of parkinsonism: selective destruction of dopaminergic neuons in the pars compacta of the substantia nigra byN-methyl-4-phenyl-1,2,3,6-tetryhydropyridine